logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. Meda Pharmaceuticals Inc.

    Meda Pharmaceuticals Inc. drugs

    FiltersReset Filters
    4 results

    • depen

      (Penicillamine)
      Meda Pharmaceuticals Inc.
      Usage: DEPEN is indicated for treating Wilson’s disease, cystinuria, and severe rheumatoid arthritis in patients who have not responded to conventional therapy. It helps minimize copper intake and promotes copper excretion in Wilson’s disease, reduces cystine excretion to prevent stone formation in cystinuria, and assists in managing severe rheumatoid arthritis.

    • dymista

      (Azelastine Hydrochloride and Fluticasone Propionate)
      Meda Pharmaceuticals Inc.
      Usage: DYMISTA is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and children aged 6 years and older.

    • felbatol

      (felbamate)
      Meda Pharmaceuticals Inc.
      Usage: Felbatol® is indicated for patients with severe epilepsy who do not respond to other treatments. It may be used as monotherapy or adjunctive therapy for partial seizures in adults, and as adjunctive therapy for partial and generalized seizures in children with Lennox-Gastaut syndrome, with associated risks acknowledged.

    • soma

      (Carisoprodol)
      Meda Pharmaceuticals Inc.
      Usage: SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. It should be used for short durations (up to three weeks) due to lack of evidence for longer-term effectiveness and the typically short duration of these conditions.